IFRX — InflaRx N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1708688 ·
Last close
$1.60
Market Cap
$235.79M
52W High
$2.95
52W Low
$0.80
ADV30
537,157
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -7,002,727 | -10,648,484 | 166,907,332 | 146,567,894 | 20,723,760 |
| Mar 2026 | 0 | 0 | -7,208,150 | -5,592,649 | 48,889,811 | 14,993,792 | 11,999,608 |
| Dec 2025 | -33,931 | -4,892,342 | -12,856,841 | -10,642,393 | 55,216,297 | 16,022,171 | 13,659,516 |
| Sep 2025 | 23,830 | 23,497 | -9,477,005 | -12,261,089 | 65,157,050 | 6,448,116 | 19,790,235 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,691,001
Investing CF
$-8,284,104
Financing CF
$6,232,457
CapEx
$-114,715
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,418,650
Inventory
$0
Receivables
$1,650,338
ST Investments
$24,806,894
EBIT TTM
$-42,757,325
Pretax Income TTM
$-42,807,287
Interest Exp TTM
$49,962
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$-10,101
EBITDA
$-35,641,328
Free Cash Flow
$-4,312,136
Enterprise Value
$150,318,272
Total Cash
$158,514,496
Total Debt
$833,179
Shares Out
147,368,221
Trailing EPS
$-0.58
Book Value
$1.15
ROE
-38.5%
ROA
-18.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,331 | -48,256,974 | -45,633,780 | 55,216,297 | 13,659,516 | 41,556,781 | -35,314,328 |
| Dec 2024 | 165,789 | -52,905,579 | -46,064,402 | 76,018,457 | 14,602,418 | 61,416,040 | -48,556,690 |
| Dec 2023 | 63,089 | -44,594,856 | -42,667,529 | 120,208,551 | 17,626,821 | 102,581,731 | -37,812,966 |
| Dec 2022 | 0 | -32,237,867 | -29,484,611 | 102,399,660 | 14,050,220 | 88,349,440 | -33,742,817 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.40
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $1.60 · call volume: 195 · put volume: 21
Expected Move to 2026-10-16:
±$0.73
(45.62%) —
implied range
$0.87 –
$2.33
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | $235.67M | $3.28 | — |
| CAMP | Camp4 Therapeutics Corp | $236.58M | $3.77 | — |
| SLGL | Sol-Gel Technologies Ltd. | $234.97M | $71.77 | — |
| KROS | Keros Therapeutics, Inc. | $236.93M | $11.95 | — |
| MGNX | MACROGENICS INC | $238.24M | $3.74 | — |
News headlines (Yahoo Finance, 1h cache)
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
2026-10-02 11:30 · Yahoo
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
2026-10-01 11:30 · Yahoo
InflaRx Announces Participation in September Investor Conferences
2026-08-20 11:30 · Yahoo
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
2026-08-06 11:30 · Yahoo
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
2026-06-30 11:30 · Yahoo
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
2026-05-31 10:55 · Yahoo
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
2026-05-08 15:53 · Yahoo
InflaRx to Report First Quarter 2026 Results on May 7, 2026
2026-05-01 11:30 · Yahoo
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
2026-04-09 11:30 · Yahoo
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
2026-05-07 17:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.